Price movement over the last 24 hours
Abbott Laboratories vs Invesco Solar ETF — how do they compare? Abbott Laboratories trades at $95.53 (market cap $166.94B), while Invesco Solar ETF trades at $53.02. The key difference: Abbott Laboratories pays a 2.63% dividend while Invesco Solar ETF pays none, and Invesco Solar ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | TAN | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $73.95 |
52-Week Low | $82.57 | $36.07 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
TAN trades at $57.54, up 2.17% today, but technical indicators signal a bearish trend with moving averages showing strong selling pressure. The ETF has evolved into a focused play on utility-scale solar and grid-connected technology, benefiting from surging electricity demand driven by AI infrastructure growth. Recent news highlights both opportunities in clean energy investment and headwinds from regulatory challenges and supply chain costs.
The outlook for TAN is mixed with strong long-term growth potential from AI-driven energy demand but near-term volatility from regulatory uncertainty and technical weakness. Investment opportunities center on the clean energy transition, while risks include policy changes, Chinese supply chain restrictions, and elevated material costs impacting solar project economics.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →